Introduction {#S1}
============

Carcinosarcomas (CSs) are rare tumours that consist of two malignant components: carcinomatous and sarcomatous, and are often associated with poor prognosis. These neoplasms have been observed in various locations, such as uterus, ovaries, breast, gastrointestinal tract, genitourinary tract, lung, breast, bones, thyroid gland, and paranasal sinuses \[[@ref1]--[@ref4]\]. The most common site of CS is the uterus, where it is referred to as mixed malignant Müllerian tumour (MMMT). The ambivalent nature of CSs raises questions about its origin. In the vast majority of tumours, a monoclonal origin of both components was proven \[[@ref5]\]. Comparative genetic analyses performed on various CSs (e.g. CS of parotid gland, urinary bladder, and pharynx) revealed a large overlap of chromosomal aberrations in both tumour components \[[@ref6], [@ref7]\].

Most authors presume that the sarcomatous component is derived from carcinoma through a process called epithelial-mesenchymal transition (EMT) \[[@ref5]\]. Physiologically, EMT is involved in the formation of the body plan during foetal development, differentiation of tissues, and their repair. Epithelial cells undergoing EMT lose the epithelial phenotype and acquire an increased migration potential. In various cancers, partial or complete EMT occurs, thus enhancing the malignant potential \[[@ref8]\]. The hypothesis of the crucial role of EMT in CS pathogenesis is supported by ultrastructural, immunohistochemical, and microRNA studies \[[@ref9]--[@ref12]\].

*TP53* mutations seem to be crucial for CS pathogenesis. In the vast majority of CSs, concordant overexpression of p53 is found in both components \[[@ref13]--[@ref15]\]. In recent years, molecular research on uterine CS has highlighted the role of p53 and mismatch repair protein (MMR) dysfunction in its pathogenesis; however, some studies produced conflicting data, and the role of *MLH1* promoter hypermethylation has not yet been evaluated in these tumours. Therefore, we investigated the p53 and MMR status in uterine CS obtained from a single institution cohort.

Material and methods {#S2}
====================

Study population {#S2_1}
----------------

Cases of CS, recorded at the University Clinical Centre in Gdansk from 2007 to 2015, were retrieved from the archive of the Department of Pathomorphology. The microscopic slides of each case were re-evaluated by two pathologists to verify the diagnosis. Twenty formalin-fixed and paraffinembedded (FFPE) tissue blocks containing representative uterine CS samples were included in our study.

Immunohistochemistry {#S2_2}
--------------------

Tumour samples were stained with antibodies against hMLH1(Clone ES05), PMS2 (Clone EP51), hMSH2 (Clone FE 11), hMSH6 (Clone EP49), and p53 (Clone DO-7), all ready to use (DAKO, Denmark). Staining was performed on a Dakoautostainer according to the manufacturer's instructions. The slides of all specimens were microscopically evaluated by two experienced pathologists (PC and WB). In the case of MMR proteins, nuclear staining was considered positive, and lack of nuclear staining -- negative (a sign of defective MMR). The question of how to correctly interpret the immunostaining for p53 is a matter of controversy. According to the current point of view, we considered a strong/diffuse (\> 75% of tumour cell nuclei) and a completely negative stain as p53 defect indicative of its mutation, (missense and nonsense, respectively), whereas a patchy/scattered pattern was regarded as a marker of normal p53 function \[[@ref16]\]. Representative pictures are given in [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}.

![Carcinosarcoma (H&E) (**A**) with loss of *MLH1* (**B**) and inhomogeneous p53 (**C**). *MLH1* promoter hypermethylation, p53 wildtype](WO-23-89635-g001){#F1}

![Carcinosarcoma (H&E) (**A**) with retained expression of *MLH1* (**B**) and strong expression of p53 (**C**). *MLH1* promoter hypermethylation, p53 mutated](WO-23-89635-g002){#F2}

DNA extraction from FFPE tissue sections {#S2_3}
----------------------------------------

Serial 6-μm slices were cut from the paraffin-embedded blocks, and the first section was stained with haematoxylin-eosin (HE) to evaluate the tumour cell content. If the tumour cell content was less than 50%, macrodissection of tumour cell-rich areas was performed. After deparaffinisation, DNA was extracted according to the standard procedure described in the Cobas^®^ DNA Sample Preparation Kit (Roche Molecular Systems, Inc., USA) package insert. The amount of genomic DNA was adjusted to fixed concentrations of 2--5 ng/μl.

*TP53* mutation analysis {#S2_4}
------------------------

*TP53* mutation status in tissue samples was assessed by PCR using MyTaq HS DNA polymerase (Bioline, Germany) through 37 cycles with appropriate annealing temperatures. Primer sequences and annealing temperatures specific for exons 4--8 of *TP53* are shown in [Table 1](#T1){ref-type="table"}. PCR samples were subjected to direct sequencing of single-stranded PCR products using a BigDye^®^ Terminator v1.1 cycle sequencing kit and an ABI 3500 genetic analyser (Applied Biosystems).

###### 

Primer sequences specific for *TP53* as well as methylated (met) and unmethylated (unmet) *MLH1* promoter

  Primer        Forward                      Reverse                    Temperature
  ------------- ---------------------------- -------------------------- -------------
  p53 exon 4    ATCTACAGTCCCCCTTGCCG         GCAACTGACCGTGCAAGTCA       60°C
  p53 exon 5    TTCACTTGTGCCCTGACTT'         ACCCTGGGCAACCAGCCCTGTC     60°C
  p53 exon 6    ACCATGAGCGCTGCTCAGAT         AGTTGCAAACCAGACCTCAGGC     60°C
  p53 exon 7    CTGCTTGCCACAGGTCTC           TGGATGGGTAGTAGTATGGAAG     60°C
  p53 exon 8    ACTGCCTCTTGCTTCTCTTT         AAGTGAATCTGAGGCATAAC       56°C
  *MLH1*unmet   GAAGAGTGGATAGTGATTTTTAATGT   ATCTCTTCATCCCTCCCTAAAACA   60°C
  *MLH1* met    AGCGGATAGCGATTTTTAACGC       TCTTCGTCCCTCCCTAAAACG      60°C

*MLH1* methylation analysis {#S2_5}
---------------------------

Bisulphite conversion of genomic DNA from tissue samples was performed using the InviGene^®^ Bisulfite Conversion Kit (STRATEC Molecular GmbH) according to the manufacturer's instructions. *MLH1* promoter methylation status was assessed by comparing normal genomic DNA with bisulphite-treated DNA of each tissue sample using methylated and unmethylated allele-specific primers and PCR conditions as described above. Primer sequences and annealing temperatures are shown in [Table 1](#T1){ref-type="table"}. PCR samples were subjected to an Agilent 2100 Bioanalyzer using the Agilent DNA 1000 Kit according to the manufacturer's instructions (Agilent Technologies).

Statistical analysis {#S2_6}
--------------------

Concordance in immunohistochemical staining between sarcomatous and carcinomatous components was evaluated with Fisher's exact test and kappa test. Other categorical variables were compared using Fisher's exact test. Correlation between MMR and p53 status was assessed by Spearman's rank-correlation test. Calculations were performed using Statistica software (Dell, version 13), licensed to the Medical University of Gdansk.

Results {#S3}
=======

Twenty patients were included in the study. Immunohistochemical staining patterns of each tumour, along with basic demographic data, are shown in [Table 2](#T2){ref-type="table"}. Median age at diagnosis was 71.5 years (range 54 to 88, average 72.5). All cases occurred in post-menopausal patients. Immunostaining for hMLH1 and PMS2 were negative in three out of 20 uterine CS (15%). In turn, immunohistochemically, hMSH2 and hMSH6 were present in all tumours. There was a concordance rate of 100% in MMR protein staining between both components (k = 1, *p*\< 0.001).

###### 

Summary of p53 and MMR alterations in current cohort of uterine carcinosarcoma

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No   Age   Mutation                             Effect                           Structural\              p53 IHC   *MLH1* meth (+/--)   Epithelial\           Sarcomatous\
                                                                                   domain-function                                         component histology   component histology
  ---- ----- ------------------------------------ -------------------------------- ------------------------ --------- -------------------- --------------------- -------------------------------------
  1    71    Exon 8: p.R272C/c.817C\>T            Missense                         L1/S/H2 -- DNA binding   AD in S   --                   Endometrioid          Heterologous\
                                                                                                                                                                 (rhabdomyosarcoma + chondrosarcoma)

  2    72    WT                                   --                               --                       N         \+                   Endometrioid          Heterologous (rhabdomyosarcoma)

  3    67    WT                                   --                               --                       N         --                   Endometrioid          Heterologous (rhabdomyosarcoma)

  4    86    Exon 5: p.V157fs\*24/c.469_470insC   Missense                         NDBL/β-sheets --\        AD        --                   Serous                Heterologous\
                                                                                   DNA binding                                                                   (rhabdomyosarcoma + fibrosarcoma)

  5    64    WT                                   --                               --                       AD        --                   Endometrioid          Heterologous\
                                                                                                                                                                 (rhabdomyosarcoma + leiomyosarcoma)

  6    61    Exon 7: p.C229G/c.685T\>G            Missense (partiallyfunctional)   NDBL/β-sheets --\        AD        --                   Undifferentiated      Heterologous (rhabdomyosarcoma)
                                                                                   DNA binding                                                                   

  7    70    WT                                   --                               --                       N         \+                   Endometrioid          Homologous

  8    60    Exon 8: p.R249S/c.747G\>T            Missense                         L2/L3 -- DNA binding     AD        --                   Serous                Heterologous (rhabdomyosarcoma)

  9    77    Exon 7: p.R248Q/c.743G\>A            Missense                         L2/L3 -- DNA binding     AD        --                   Serous                Homologous

  10   81    Exon 5: p.A159V/c.476C\>T            Missense                         NDBL/β-sheets --\        AD        --                   Undifferentiated      Heterologous (chondrosarcoma)
                                                                                   DNA binding                                                                   

  11   88    WT                                   --                               --                       AD        --                   Serous                Homologous

  12   74    WT                                   --                               --                       N         --                   Endometrioid          Homologous

  13   81    Exon 8: p.R273L/c.818G\>T            Missense                         L1/S/H2 --\              AD        --                   Serous                Heterologous (rhabdomyosarcoma)
                                                                                   DNA binding                                                                   

  14   62    WT                                   --                               --                       N         \+                   Endometrioid          Heterologous (rhabdomyosarcoma)

  15   73    WT                                   --                               --                       AD        --                   Serous                Homologous

  16   54    WT                                   --                               --                       N         --                   Undifferentiated      Homologous

  17   64    WT                                   --                               --                       N         --                   Undifferentiated      Homologous

  18   64    WT                                   --                               --                       N         --                   Serous                Homologous

  19   75    Exon 6: p.H193R/c.578A\>G            Missense                         L2/L3 --\                AD in S   \+                   Serous                Heterologous (rhabdomyosarcoma)
                                                                                   DNA binding                                                                   

  20   80    NA                                   NA                               NA                       AD        NA                   Serous                Homologous
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IHC -- immunohistochemistry, WT -- wildtype, AD -- abnormaldiffuse, N -- normal, S -- sarcoma

We detected abnormal IHC expression of p53 in 12 of 20 samples (60%). In the vast majority of cases (18/20, 90.0%) there was concordance between the sarcomatoid and carcinomatous components (k = 0.895, *p*\< 0.001). Aberrant p53 staining was strong/diffuse in all cases.

Interestingly, we observed that in all three cases with defective MMR, there was no immunohistochemical evidence of any p53 defect; on the other hand, all uterine tumours with defective p53 were positive for MMR proteins. Thus, in the next step, we tested the *MLH1* promoter methylation status and *TP53* mutations in our cohort (one case was excluded due to the lack of representative material for further analyses). *TP53* mutation was detected in 8/19 tumours (42.1%), whereas *MLH1* promoter hypermethylation occurred in 4/19 cases (21%). Only one case showed a simultaneous defect in *TP53* and hMLH1 (5%). *TP53* mutations were found exclusively in regions responsible for DNA binding, and some of them had been previously observed in uterine CS. Agreement between the results of the genetic and immunohistochemical study was moderate for p53 (k = 0.615, *p*\< 0.01) and strong for hMLH1 (k = 0.826, *p*\< 0.01). Correlation between p53 and hMLH1 defect in uterine CS, assessed by Spearman's rank-correlation, was --0.40849 (*p* = 0.0825).

Discussion {#S4}
==========

We hypothesised that loss of mismatch repair (MMR) proteins and p53 expression, caused by genome instability and generation of either microsatellite (MSI) or chromosomal instability (CIN), may play a role in the pathogenesis of uterine CS. It is well known that MMR-deficiency and *TP53* mutations, either gain or loss of function, may lead to the development of the sarcomatous component, for example through TGF-bsignalling (by MMR deficiency) \[[@ref17]\] or miRNA \[[@ref18], [@ref19]\].

In previous studies, conflicting results have been published. In their prototypical study, Taylor *et al*. examined 28 uterine CS for MSI and MMR protein (hMLH1, hMSH2, and hMSH6) expression and *TP53* status \[[@ref20]\]. Six tumours (21%) displayed defective DNA mismatch repair owing to the high-level MSI (MSI-H) phenotype in at least one component. Interestingly,immunostaining was negative for hMLH1, hMSH2, and hMSH6 \[[@ref20]\] in only two of six cases with MSI-H. Other studies reported IHC MMR protein loss in CSs at various frequencies, ranging from 3% to 40% \[[@ref21]--[@ref23]\]. Only one study reported frequent IHC loss of hMSH2 and hMSH6 in CS \[[@ref23]\]. However, the results of the IHC studies of MMR proteins without molecular confirmation should be interpreted with caution. The MSI frequency in CS of the female genital tract ranges from 5% to 23% of cases \[[@ref20]--[@ref22], [@ref24], [@ref25]\]. Overall, the frequency of MMR defects assessed with the use of various methods reported in the literature is 13% \[[@ref26]\]. The two main mechanisms of MMR loss in cancer are sequence mutations and epigenetic changes. Extensive parallel sequencing of 22 uterine CSs revealed *MLH1* frameshift mutation in one case (5%) and *MSH6* nonsense mutation in three cases (15%) \[[@ref27]\]. A recent comprehensive epigenetic analysis of 57 uterine CS cases revealed *MLH1* epigenetic silencing in two tumours exhibiting MSI, discovering a novel important mechanism responsible for MMR deficiency in uterine CS \[[@ref28]\]. Our study reports another four cases of *MLH1* promoter methylation in CS, which supports these findings.

We have observed MMR defect in 15% of cases according to the IHC and 21% according to the *MLH1* promotor hypermethylation analysis. This discrepancy was shown in a previous study from Australia; in 702 endometrial cancer patients it was demonstrated that 3% of MMR-proficient tumours showed *MLH1* promoter methylation, and the methylation levels in these cases were low \[[@ref29]\].

Taylor's cohort and ours showed a tendency towards an inverse association between MMR and p53 status \[[@ref20]\]. Only one tumour from our cases presented with *MLH1* hypermethylation and *TP53* mutation; however, it was still positive immunohistochemically. Moreover, in our cohort, *MLH1* promoter hypermethylation occurred preferentially in cases with the endometrioid epithelial component, whereas p53 aberrations were seen in CS with the serous or undifferentiated component. These findings are consistent with another study that demonstrated a higher frequency of p53 defects in CS with serous differentiation when compared with CS with an endometrioid epithelial component \[[@ref30]\]. Genetic studies showed that the overall mutation profile of uterine CS corresponds to the mutation profiles of either serous (mutation of *TP53* and *PPP2R1A*) or endometrioid carcinomas (mutation of *PTEN* and *ARID1A*) \[[@ref21], [@ref31]\]. Nevertheless, these findings are not supported by other studies that failed to demonstrate any inverse associations between mutations in MMR genes and *TP53* \[[@ref21], [@ref28]\].

Conclusions {#S5}
===========

We conclude that epigenetic loss of hMLH1 expression may be an element of pathogenesis in some cases of uterine CS. In our cohort, the MMR defect tended to show an inverse correlation with p53 abnormalities. This association may indicate the existence of two distinct pathways of uterine CS development: through microsatellite or chromosomal instability. As CSs are rare tumours, multicentre studies are required to better explain the role of these alternations in tumours originating from the uterus and other organs.
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